Which are the most exciting areas of orphan drug research and where are the best opportunities?
Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209 billion by 2022. Orphan drugs enjoy favourable regulatory pathways, satisfy unmet clinical need and often command significant prices. No wonder that research efforts have intensified and the number of molecules gaining orphan drug designation is growing year-on-year. But which are the most promising therapies and conditions? Where is investment being made? Which companies/developers are setting the pace?
Charting the Orphan Drug Development Pipeline analyses 3,868 unique molecules from 2,257 developers to create the most comprehensive independent analysis of orphan drug research activity available. This comprehensive report, and its associated MS Excel™ data set, reveals developments in the context of EMA/FDA designation status, therapy areas, conditions, developers and clinical trial activity.
Two Extensive Information and Data Resources Included
Analysis Report: Organised by therapy area, the report, through more than 420 easy-to-read charts, tables and figures, identifies the designation status, conditions being targeted, the leading developers and the current/planned clinical trial landscape
MS Excel Data: This powerful resource allows you to really drill down into the data for key insights. All the data in the report is included in a well-structured MS Excel Spreadsheet for your own further analysis or incorporation into internal data analytics platforms.
This Unrivalled Resource Provides
A comprehensive overview of the market dynamics, legal definition and US/EU incentives for orphan drugs
An analysis of orphan drug designation trends 2015-2016 by therapy area in the US and EU
A review of FDA and EMA orphan drug designation status by therapy area
Extensive reviews by therapeutic category identifying FDA and EMA designation status with a focus on the number of orphan drug designations issued between January 2016 and March 2017
The orphan diseases and conditions that are attracting developer interest and research effort
At a glance overview of companies’ orphan drug portfolios
An overview of 1,019 trials from 207 sponsors covering the number of active, dormant, recruiting and completed clinical trials within each therapy area
Reasons to Buy
Key Report Facts
37213 Data Points
20 Therapy Areas
Identify the trends and status of orphan drugs in 20 major therapy areas
Compare the difference in orphan drug designations between the FDA and the EMA
Examine the rare diseases which are attracting research interest and investment
Assess how a company’s orphan drug research programme indicates its ambitions
Understand how clinical trial activity is reflecting interest in key therapy areas and know who’s involved
Incorporate all the data into your internal data analytics systems.
Key Questions Answered By This Report
Cardiovascular: What is the leading target condition in the cardiovascular area?
Gastrointestinal: There are 9 drugs being researched for short bowel syndrome, but which companies are involved in this area?
Genitourinary: How many drugs received orphan drug designation from the EMA in 2016?
Haematology: Which 3 companies are leading the orphan drug research push?
Neuroscience: 12 orphan drugs are in Phase III trials – what are they and who are the developers?
Metabolic disease: What is the target enrolment to clinical trials for abatacept, osilodrostat and metyrapone in the metabolic disease area?
Oncology: What cancers are attracting the most developer interest and how is this reflected in the number of orphan drug designations?
Who Will Benefit from this Report?
Corporate leaders looking to position their company in niche orphan disease opportunity areas
Business development teams profiling potential acquisition or collaboration opportunities
Research managers planning clinical research programmes
Regulatory teams applying for and monitoring trends in FDA and EMA orphan drug designation
Competitive intelligence professionals tracking the activity of key competitors in their field of interest
Financial and consultancy professionals identifying investment opportunities.
Report Content Highlights
Orphan drug market dynamics
Legal definitions and incentives for orphan drug development in US and EU
Trends in orphan drug designation
For each therapy area covered
EU/US designated drugs
Orphan drugs designated in 2016-2017
Clinical Trials: Molecules, sponsors and trial end dates
MS Excel Dataset Gives Instant Access to
FDA/EU Designation Date
Brand (if relevant)
Therapy Areas Covered
Gynaecology and obstetrics
Haematology (blood and blood clotting)
Hormonal (excluding sex hormones)
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.